排序方式: 共有29条查询结果,搜索用时 15 毫秒
11.
L. Lee Dupuis MScPhm ACPR FCSHP Sabrina Boodhan BScPhm ACPR Mark Holdsworth PharmD BCOP Paula D. Robinson MD MSc Richard Hain MD Carol Portwine MD FRCPC PhD Erin O'Shaughnessy RN MScN CPHON Lillian Sung MD PhD 《Pediatric blood & cancer》2013,60(7):1073-1082
This guideline provides an approach to the prevention of acute antineoplastic‐induced nausea and vomiting (AINV) in children. It was developed by an international, inter‐professional panel using AGREE and CAN‐IMPLEMENT methods. Evidence‐based interventions that provide optimal AINV control in children receiving antineoplastic agents of high, moderate, low, and minimal emetogenicity are recommended. Recommendations are also made regarding selection of antiemetic agents for children who are unable to receive corticosteroids for AINV control, the role of aprepitant and optimal doses of antiemetic agents. Gaps in the evidence used to support the recommendations were identified. The contribution of this guideline to AINV control in children requires prospective evaluation. Pediatr Blood Cancer 2013; 60: 1073–1082. © 2013 Wiley Periodicals, Inc. 相似文献
12.
Jamie F. Shapiro PharmD BCOP Judy L. Chase PharmD Robert A. Wolff MD Laura A. Lambert MD Paul F. Mansfield MD Michael J. Overman MD Aki Ohinata PA Jun Liu MS Xuemei Wang MS Cathy Eng MD 《Cancer》2010,116(2):316-322
BACKGROUND:
Appendiceal neoplasms include tumors ranging from benign‐appearing cells with widespread mucin deposits to aggressive poorly differentiated signet ring cell adenocarcinomas. Traditionally, these tumors are treated with cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy. For some patients, cytoreductive surgery is not an option, and minimal published data exist in the management and outcome of these patients. A retrospective analysis was conducted to determine the benefit of modern systemic chemotherapy in patients with disseminated appendiceal neoplasm who were not considered optimal candidates for cytoreductive surgery.METHODS:
A retrospective review was conducted using The University of Texas M. D. Anderson Cancer Center tumor registry between January 2000 and July 2005. Response was determined by radiographic response and/or overall clinical benefit.RESULTS:
Of 186 patients diagnosed with appendiceal neoplasm, 54 (29%) patients considered to be suboptimal surgical candidates received ≥2 cycles of systemic chemotherapy. Thirty (55.6%) patients had a disease control rate noted as a complete response, partial response, or stable disease. After a median follow‐up of 24 months, the median progression‐free survival (PFS) and overall survival were determined to be 7.6 months (95% confidence interval [CI], 4‐11) and 56 months (95% CI, 36‐not applicable), respectively.CONCLUSIONS:
Systemic chemotherapy has a role in appendiceal neoplasm patients who are suboptimal candidates for cytoreductive surgery. The intermediate PFS indicates the challenges that exist for appendiceal neoplasm patients in this setting. Prospective randomized trials including systemic chemotherapy are needed to provide further insight into this malignancy, for which no standard exists. Cancer 2010. © 2010 American Cancer Society. 相似文献13.
Development and clinical application of an evidence‐based pharmaceutical care service algorithm in acute coronary syndrome 下载免费PDF全文
14.
Patient‐reported outcomes from EMILIA,a randomized phase 3 study of trastuzumab emtansine (T‐DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2–positive locally advanced or metastatic breast cancer 下载免费PDF全文
15.
Magnesium monitoring practice in monoclonal anti‐epidermal growth factor receptor antibodies therapy
16.
17.
18.
Nisha S. Joseph MD Jonathan L. Kaufman MD Lawrence H. Boise PhD Kelly Valla PharmD BCOP Dhwani K. Almaula MBBS Chikaodili O. Obidike BDS MPH Amelia A. Langston MD Edmund K. Waller MD PhD Hanna J. Khoury MD Christopher R. Flowers MD MS Michael Graiser PhD Leonard T. Heffner MD Sagar Lonial MD FACP Ajay K. Nooka MD MPH FACP 《Cancer》2019,125(2):185-193
High-dose therapy (HDT) and autologous stem cell transplantation (ASCT) are established components in the treatment of multiple myeloma; however, undergoing transplantation usually requires hematopoietic support, which poses a challenge among patients who are unwilling to receive blood products. Most transplant centers decline HDT/ASCT to these patients because of safety concerns. Here, the authors’ institutional data on safety, engraftment parameters, and survival outcomes after bloodless ASCT (BL-ASCT) are examined among patients with myeloma. This retrospective case-control study included patients who underwent BL-ASCT and Transfusion-supported ASCT (TS-ASCT) at Emory University Hospital between August 2006 and August 2016. In total, 24 patients who underwent BL-ASCT and 70 who underwent TS-ASCT were included. The median time for neutrophil engraftment, platelet engraftment and the median length of hospital stay all were equivalent for both groups. There were no transplant-related cardiovascular complications or mortality in either the BL-ASCT group or the TS-ASCT group. The median progression-free survival was 36 months and 44 months in the BL-ASCT and TS-ASCT groups, respectively (P = .277), and the median OS was not reached in either group at a median follow-up of 59 months after ASCT (P = .627). There was no transplant-related mortality at the 100-day or 1-year mark in either group. BL-ASCT is safe and feasible; transplant-related mortality, cardiovascular and hematologic complications are similar to those associated with TS-ASCT. Furthermore, BL-ASCT can yield similar engraftment and survival parameters comparable to those observed with TS-ASCT. 相似文献
19.
20.
Sarah M. Temkin MD Matthew P. Smeltzer PhD MStat Monique D. Dawkins EdD MPA Leigh M. Boehmer PharmD BCOP Leigha Senter MS LGC Destin R. Black MD Stephanie V. Blank MD Anna Yemelyanova MD Anthony M. Magliocco MD Mollie A. Finkel RN MSN WHNP-BC AOCNP-BC Tracy E. Moore LCSW Premal H. Thaker MD 《Cancer》2022,128(4):654-664
The high lethality of ovarian cancer in the United States and associated complexities of the patient journey across the cancer care continuum warrant an assessment of current practices and barriers to quality care in the United States. The objectives of this study were to identify and assess key components in the provision of high-quality care delivery for patients with ovarian cancer, identify challenges in the implementation of best practices, and develop corresponding quality-related recommendations to guide multidisciplinary ovarian cancer programs and practices. This multiphase ovarian cancer quality-care initiative was guided by a multidisciplinary expert steering committee, including gynecologic oncologists, pathologists, a genetic counselor, a nurse navigator, social workers, and cancer center administrators. Key partnerships were also established. A collaborative approach was adopted to develop comprehensive recommendations by identifying ideal quality-of-care program components in advanced epithelial ovarian cancer management. The core program components included: care coordination and patient education, prevention and screening, diagnosis and initial management, treatment planning, disease surveillance, equity in care, and quality of life. Quality-directed recommendations were developed across 7 core program components, with a focus on ensuring high-quality ovarian cancer care delivery for patients through improved patient education and engagement by addressing unmet medical and supportive care needs. Implementation challenges were described, and key recommendations to overcome barriers were provided. The recommendations emerging from this initiative can serve as a comprehensive resource guide for multidisciplinary cancer practices, providers, and other stakeholders working to provide quality-directed cancer care for patients diagnosed with ovarian cancer and their families. 相似文献